<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00621998</url>
  </required_header>
  <id_info>
    <org_study_id>TMH-91-02</org_study_id>
    <secondary_id>DOH-890010</secondary_id>
    <nct_id>NCT00621998</nct_id>
  </id_info>
  <brief_title>Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia</brief_title>
  <official_title>A Randomized Controlled Trial of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We initiate a study with research grant from department of health and Taoyuan mental hospital&#xD;
      and choose risperidone and olanzapine as study medications. We compare the effects of these 2&#xD;
      drugs in schizophrenic spectrum patients of Han ethnics with neuroleptic-induced tardive&#xD;
      dyskinesia to test the hypothesis that these two medications have different effects in&#xD;
      improving tardive dyskinesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: First generation antipsychotics would induce tardive dyskinesia in some&#xD;
      schizophrenic patients. Second generation antipsychotics were the choices for these patients.&#xD;
      But which one of second generation antipsychotic was the better choice did not have&#xD;
      definitive results. We compared risperidone and olanzapine in schizophrenic patients with&#xD;
      neuroleptic-induced tardive dyskinesia to see their effects in improving tardive dyskinesia.&#xD;
      We also collected the data of average dose of risperidone and olanzapine to help the dosing&#xD;
      strategy guidelines for the schizophrenic patients with neuroleptic-induced tardive&#xD;
      dyskinesia.&#xD;
&#xD;
      Method: This randomized, rater-blind, parallel group, flexible dose study enrolled patients&#xD;
      from Taoyuan Mental Hospital from July 2000 to December 2003. Schizophrenia, schizophreniform&#xD;
      or schizoaffective disorder (DSM-IV) patients who met the research criteria of&#xD;
      neuroleptic-induced tardive dyskinesia research criteria of DSM-IV and no less than moderate&#xD;
      severity (&gt; or =4) of global impression of extrapyramidal syndrome rating scale (ESRS). 60&#xD;
      patients were random assignment to risperidone or olanzapine for 24 weeks. The primary&#xD;
      outcome was to compare the change of total scores of abnormal involuntary movement scale from&#xD;
      baseline to study endpoint.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total scores of AIMS</measure>
    <time_frame>The change from baseline to study endpoint</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total scores of BPRS</measure>
    <time_frame>The change from baseline to study endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extrapyramidal syndrome rating scale</measure>
    <time_frame>The change from baseline to study endpoint</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Neuroleptic-Induced Tardive Dyskinesia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flexible dose of olanzapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Flexible dose of risperidone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone</intervention_name>
    <description>0.5-6 mg/day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>2.5-20 mg/day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of 18-70 y/o&#xD;
&#xD;
          -  Female patients did not have pregnancy plans and must agree to use reliable pregnancy&#xD;
             prevention methods if during childbearing age&#xD;
&#xD;
          -  Meet schizophrenia, schizophreniform or schizoaffective disorder criteria of DSM-IV&#xD;
&#xD;
          -  Fulfill DSM-IV neuroleptic-induced tardive dyskinesia research criteria, the severity&#xD;
             of tardive dyskinesia was no less than moderate degree (&gt; or =4) assessed by global&#xD;
             impression of Extrapyramidal System Rating Scale (item 42 of ESRS)&#xD;
&#xD;
          -  Patients or legal responsible people agree to join study and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Had other axis I diagnosis of DSM-IV&#xD;
&#xD;
          -  Unstable major systemic diseases&#xD;
&#xD;
          -  Had neurological disorder influenced to EPS assessment&#xD;
&#xD;
          -  Substance abuse or dependence other then coffee or tobacco within 6 months before&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hung-Yu Chan, M.D., M.S.</last_name>
    <role>Study Chair</role>
    <affiliation>Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taoyuan Mental Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>33058</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2000</verification_date>
  <study_first_submitted>February 13, 2008</study_first_submitted>
  <study_first_submitted_qc>February 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2008</study_first_posted>
  <last_update_submitted>February 13, 2008</last_update_submitted>
  <last_update_submitted_qc>February 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Hung-Yu Chan/ Attending Psychiatry and Director of General Psychiatry</name_title>
    <organization>Taoyuan Mental Hospital</organization>
  </responsible_party>
  <keyword>Risperidone</keyword>
  <keyword>Olanzapine</keyword>
  <keyword>Tardive dyskinesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Tardive Dyskinesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

